Patents Assigned to Novartis Vaccines and Diagnostics
-
Patent number: 11034759Abstract: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.Type: GrantFiled: October 12, 2018Date of Patent: June 15, 2021Assignees: Novartis Vaccines and Diagnostics, Inc., Xoma Technology Ltd.Inventors: Cheng Liu, Deborah Lee Zimmerman, Gregory Martin Harrowe, Kirston Koths, William Michael Kavanaugh, Li Long, Maria Calderon-Cacia, Arnold Horwitz
-
Publication number: 20180221446Abstract: The present invention provides a unit dose comprising 0.2 ?g/kg to 36 ?g/kg of a recombinant FGF or an angiogenically active fragment or mutein thereof. Also provided is a pharmaceutical composition comprising an angiogenically effective dose of an FGF or an angiogenically active fragment or mutein thereof, and a pharmaceutically acceptable carrier. Also provided is a method for treating a human patient for coronary artery disease, comprising administering into at least one coronary vessel of said patient a safe and angiogenically effective dose of a recombinant FGF of any of SEQ ID NOS: 1-3, 5, 8-10, or 12-14, or an angiogenically active fragment or mutein thereof.Type: ApplicationFiled: September 8, 2017Publication date: August 9, 2018Applicant: Novartis Vaccines and Diagnostics, Inc.Inventors: Martha J. Whitehouse, W. Michael Kavanaugh
-
Patent number: 9926371Abstract: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.Type: GrantFiled: November 9, 2016Date of Patent: March 27, 2018Assignees: NOVARTIS VACCINES AND DIAGNOSTICS, INC., XOMA TECHNOLOGY LTD.Inventors: Cheng Liu, Deborah Lee Zimmerman, Gregory Martin Harrowe, Kirston Koths, William Michael Kavanaugh, Li Long, Maria Calderon-Cacia, Arnold Horwitz
-
Patent number: 9730997Abstract: Described herein are compositions and methods for stimulating an immune response to one or more proteins derived from one or more respiratory pathogens. In particular, the invention relates to alphavirus replicons, alphavirus vector constructs, alphavirus replicon particles expressing one or more antigens derived from one or more respiratory pathogens as well as to method of making and using these immunogenic compositions.Type: GrantFiled: August 20, 2014Date of Patent: August 15, 2017Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Silvia Perri, John Polo, Yasushi Uematsu, Catherine Greer
-
Publication number: 20170152311Abstract: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.Type: ApplicationFiled: November 9, 2016Publication date: June 1, 2017Applicants: NOVARTIS VACCINES AND DIAGNOSTICS INC., XOMA TECHNOLOGY LTD.Inventors: Cheng Liu, Deborah Lee Zimmerman, Gregory Martin Harrowe, Kirston Koths, William Michael Kavanaugh, Li Long, Maria Calderon-Cacia, Arnold Horwitz
-
Publication number: 20170081416Abstract: Compositions and methods of therapy for treating diseases mediated by stimulation of CD40 signaling on CD40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of human CD40-expressing cells, such as B cells.Type: ApplicationFiled: August 19, 2016Publication date: March 23, 2017Applicant: Novartis Vaccines and Diagnostics, Inc.Inventors: Li Long, Mohammad Luqman (deceased), Asha Yabannavar, Isabel Zaror, Sang Hoon Lee, Deborah Hurst
-
Patent number: 9598469Abstract: The present invention relates to polynucleotides encoding immunogenic HIV polypeptides. Uses of the polypeptides in applications including immunization, generation of packaging cell lines, and production of HIV polypeptides are also described. Polynucleotides encoding antigenic HIV polypeptides are described, as are uses of these polynucleotides and polypeptide products therefrom, including formulations of immunogenic compositions and uses thereof.Type: GrantFiled: December 26, 2013Date of Patent: March 21, 2017Assignees: Novartis Vaccines and Diagnostics, Inc., University of StellenboschInventors: Jan Zur Megede, Susan Barnett, Ying Lian, Susan Engelbrecht, Estrelita Janse Van Rensberg, Thomas J. Scriba
-
Patent number: 9522186Abstract: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.Type: GrantFiled: June 3, 2015Date of Patent: December 20, 2016Assignees: NOVARTIS VACCINES AND DIAGNOSTICS INC., XOMA TECHNOLOGY LTD.Inventors: Cheng Liu, Deborah Lee Zimmerman, Gregory Martin Harrowe, Kirston Koths, William Michael Kavanaugh, Li Long, Maria Calderon-Cacia, Arnold Horwitz
-
Patent number: 9428739Abstract: Immunogenic compositions that elicit immune responses against Norovirus and Sapovirus antigens are described. In particular, the invention relates to polynucleotides encoding one or more capsid proteins or other immunogenic viral polypeptides from one or more strains of Norovirus and/or Sapovirus, coexpression of such immunogenic viral polypeptides with adjuvants, and methods of using the polynucleotides in applications including immunization and production of immunogenic viral polypeptides and viral-like particles (VLPs). Methods for producing Norovirus- or Sapovirus-derived multiple epitope fusion antigens or polyproteins and immunogenic compositions comprising one or more immunogenic polypeptides, polynucleotides, VLPs, and/or adjuvants are also described.Type: GrantFiled: November 27, 2012Date of Patent: August 30, 2016Assignee: NOVARTIS VACCINES AND DIAGNOSTICS, INC.Inventors: Doris Coit, Michael Houghton, Colin McCoin, Angelica Medina-Selby, Michael Vajdy
-
Publication number: 20160120943Abstract: The present invention provides a unit dose comprising 0.2 ?g/kg to 36 ?g/kg of a recombinant FGF or an angiogenically active fragment or mutein thereof. Also provided is a pharmaceutical composition comprising an angiogenically effective dose of an FGF or an angiogenically active fragment or mutein thereof, and a pharmaceutically acceptable carrier. Also provided is a method for treating a human patient for coronary artery disease, comprising administering into at least one coronary vessel of said patient a safe and angiogenically effective dose of a recombinant FGF of any of SEQ ID NOS:1-3, 5, 8-10, or 12-14, or an angiogenically active fragment or mutein thereof.Type: ApplicationFiled: September 28, 2015Publication date: May 5, 2016Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.Inventors: Martha J. Whitehouse, W. Michael Kavanaugh
-
Patent number: 9255126Abstract: Chimeric alphavirus particles and alphavirus replicon RNAs are provided including methods of making and using same. The alphavirus replicon RNAs comprise deletions in one or more nonstructural proteins. Methods of making, using, and therapeutic preparations containing the chimeric alphavirus particle are disclosed.Type: GrantFiled: August 10, 2009Date of Patent: February 9, 2016Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: John M. Polo, Silvia Perri, Kent Thudium, Zequn Tang
-
Publication number: 20160015809Abstract: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.Type: ApplicationFiled: June 3, 2015Publication date: January 21, 2016Applicants: NOVARTIS VACCINES AND DIAGNOSTICS INC., XOMA TECHNOLOGY LTD.Inventors: Cheng Liu, Deborah Lee Zimmerman, Gregory Martin Harrowe, Kirston Koths, William Michael Kavanaugh, Li Long, Maria Calderon-Cacia, Arnold Horwitz
-
Publication number: 20150299269Abstract: Influenza viruses have traditionally been administered by intramuscular injection. The invention is based on the idea of using alternative routes of delivery for influenza vaccines, more specifically routes that do not require as large a dose of antigen. Delivery of influenza antigen to the Langerhans cells is the route of choice according to the invention. This route has been found to be particularly useful for vaccinating patients who are naïve to influenza virus (i.e. have not previously mounted an immune response to an influenza virus), which means that it is advantageous for immunising young children.Type: ApplicationFiled: March 30, 2015Publication date: October 22, 2015Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.Inventor: Derek O'HAGAN
-
Patent number: 9102729Abstract: Polypeptides comprising non-typeable Haemophilus influenzae (NTHi) amino acid sequences. Over 2500 specific NTHi proteins are disclosed. The invention also provides related polypeptides, nucleic acids, antibodies and methods. These can all be used in medicine for treating or preventing disease and/or infection caused by H. influenzae, such as otitis media.Type: GrantFiled: April 29, 2014Date of Patent: August 11, 2015Assignee: Novartis Vaccines and Diagnostics SRLInventors: Vega Masignani, Beatrice Maria Arico
-
Patent number: 9079956Abstract: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.Type: GrantFiled: February 3, 2014Date of Patent: July 14, 2015Assignees: NOVARTIS VACCINES AND DIAGNOSTICS INC., XOMA TECHNOLOGY LTD.Inventors: Cheng Liu, Deborah Lee Zimmerman, Gregory Martin Harrowe, Kirston Koths, William M. Kavanaugh, Li Long, Maria Calderon-Cacia, Arnold Horwitz
-
Publication number: 20150174234Abstract: Influenza vaccines with oil-in-water emulsion adjuvants are known. The amount of emulsion adjuvant required for an influenza vaccine can be reduced, thereby allowing more vaccines to be made from a given amount of emulsion, and/or minimizing the amount of emulsion that has to be produced for a given number of vaccine doses. These vaccines can conveniently be made by mixing (i) an oil-in-water emulsion and (ii) an aqueous preparation of an influenza virus antigen. In one aspect, substantially equal volumes of components (i) and (ii) are used; in another aspect, an excess volume of component (ii) is used. When using substantially equal volumes, component (ii) has a hemagglutinin concentration of more than 60 ?g per influenza virus strain per ml. Components (i) and (ii) can be presented in kit form.Type: ApplicationFiled: December 17, 2014Publication date: June 25, 2015Applicant: NOVARTIS VACCINES AND DIAGNOSTICS SRLInventor: Mario CONTORNI
-
Patent number: 9056912Abstract: The invention includes a GAS antigen, GAS 40, which is particularly suitable for use either alone or in combinations with additional GAS antigens, such as GAS 117, GAS 130, GAS 277, GAS 236, GAS 40, GAS 389, GAS 504, GAS 509, GAS 366, GAS 159, GAS 217, GAS 309, GAS 372, GAS 039, GAS 042, GAS 058, GAS 290, GAS 511, GAS 533, GAS 527, GAS 294, GAS 253, GAS 529, GAS 045, GAS 095, GAS 193, GAS 137, GAS 084, GAS 384, GAS 202, and GAS 057.Type: GrantFiled: September 9, 2013Date of Patent: June 16, 2015Assignee: Novartis Vaccines and Diagnostics, SRLInventors: Guido Grandi, John Telford, Giuliano Bensi
-
Patent number: 9040055Abstract: Three conjugation methods for use with the capsular saccharide of Streptococcus agalactiae. In the first method, reductive animation of oxidized sialic acid residue side chains is used, but the aldehyde groups are first aminated, and then the amine is coupled to a carrier via a linker. In the second method, sialic acid residues and/or N-acetyl-glucosamine residues are de-N-acetylated to give amine groups, and the amine groups are coupled to a carrier protein via a linker. In the third method, linkage is via galactose residues in the capsular saccharide rather than sialic acid residues, which can conveniently be achieved using galactose oxidase.Type: GrantFiled: June 7, 2013Date of Patent: May 26, 2015Assignee: NOVARTIS VACCINES AND DIAGNOSTICS SRLInventor: Francesco Berti
-
Patent number: 9024001Abstract: Provided herein are modified, functional 5? amplification sequences that are defective packaging signals. Also provided are compositions and methods comprising these modified 5? amplification sequences.Type: GrantFiled: May 20, 2005Date of Patent: May 5, 2015Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Zequn Tang, Silvia Perri, John Polo
-
Patent number: 8945589Abstract: This application relates to Group B Streptococcus (“GBS”) vaccines comprising combinations of GBS polypeptide antigens where the polypeptides contribute to the immunological response in a recipient. Preferably, the compositions of the invention comprise a combination of two or more GBS antigens, wherein said combination includes GBS 80 or a fragment thereof. In one embodiment, the combination may consist of two to thirteen GBS antigens selected from an antigen group consisting of GBS 80, GBS 91, GBS 104, GBS 184, GBS 276, GBS 305, GBS 322, GBS 330, GBS 338, GBS 361, GBS 404, GBS 690, and GBS 691.Type: GrantFiled: September 15, 2004Date of Patent: February 3, 2015Assignee: Novartis Vaccines and Diagnostics, SRLInventors: John Telford, Guido Grandi, Immaculada Margarit Y Ros, Domenico Maione